Agalsidase alfa (Replagal®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000455
English
Authors' recommendations:
Agalsidase alfa (Replagal®) should be recommended for use within NHS Wales as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
Patients receiving agalsidase alfa (Replagal®) will be entered into the Fabry Outcomes Survey. AWMSG urge the manufacturers of agalsidase alfa and agalsidase beta to develop a combined outcomes database.
Treatment will be administered under the supervision of a physician experienced in the management of Fabry disease or other inherited metabolic diseases.
Treatment will be administered according to agreed guidelines at appropriate designated centres.
AWMSG will review this and other enzyme replacement therapies within three years.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=89095&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- alpha-Galactosidase
- Isoenzymes
- Fabry Disease
- Enzyme Replacement Therapy
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.